As
you know, there are two types of diabetes: Type 1, in which the immune cells
destroy the pancreatic cells that synthesize and secrete insulin; and Type 2,
in which pancreatic cells still produce insulin, but its effectiveness is
compromised. Type 1 used to be called “juvenile” diabetes, and Type 2 was
called “adult-onset” diabetes. Here’s something I didn’t know: adults can get Type
1 diabetes and children can get Type 2 diabetes.
Anyhow,
in the past, people used to be treated with cow insulin because there was no
source of human insulin. But a lot of people were allergic to cow insulin. A
scientist by the name of Arthur D. Riggs figured out how to use recombinant DNA
technology to convert bacteria into factories that produce human insulin. He
made his discovery while working at the City of Hope National Medical Center in
Duarte, California. In order to produce the human insulin, Riggs partnered with
scientists at the biotech company Genentech. In 1982, the FDA approved a human
insulin product called Humulin.
The
partnership made Genentech and Dr. Riggs rich. But Dr. Riggs declined the
opportunity to make even more money working in the for-profit sector. After his
contract with Genentech ended, he returned to City of Hope full time, living in
the same modest house for fifty years. He died this year at the age of 82. He
donated $310 million to City of Hope, most of it anonymously.
The
price of insulin has nearly tripled over the last fifteen years. A single vial
of Humalog (a fast-acting insulin) cost $21 in 1999. In 2019, it cost $332—an increase
of more than 1,500 percent. In Canada, the price didn’t budge. The difference
is that in the U.S., there’s neither a real free market nor government price
controls for insulin. Instead, there’s an oligopoly of three drug companies—Eli
Lilly, Novo Nordisk, and Sanofi—that appear to set prices in sync. In other
words, price fixing. I’m sure this is not what Dr. Riggs had envisioned.
For an introduction to this blog, see I Just Say No; for a list of blog topics, click the Topics tab.
No comments:
Post a Comment